<DOC>
	<DOCNO>NCT00745615</DOCNO>
	<brief_summary>This continuation LAQ/5063 study multinational , multicenter , randomize , double-blind , parallel group study , assess safety , tolerability efficacy two dos laquinimod subject R-R MS follow open label phase laquinimod 0.6 mg daily ( LAQ/5063 OL ) . Subjects enter randomize , two active arm study immediately completion LAQ/5062 core study . Subjects enter open-label phase ( LAQ/5063 OL ) upon termination visit LAQ/5063 active double-blind phase Subjects previously treat placebo LAQ/5062 study equally randomize one active treatment group : 0.6 mg laquinimod per o ( p.o . ) daily 0.3 mg laquinimod p.o . daily Subjects previously treat laquinimod 0.6 mg laquinimod 0.3 mg continue original treatment assignment . The LAQ/5063 study assess 0.3mg 0.6mg daily dos laquinimod patient complete LAQ/5062 study . Upon termination visit LAQ/5063 active double-blind phase ( completion full 36 week request Sponsor ) meeting eligibility criterion open-label phase , subject begin treatment laquinimod 0.6 mg daily 24 month In current phase , open-label extension extend additional 36 month treatment laquinimod 0.6mg daily .</brief_summary>
	<brief_title>An Open Label Extension LAQ/5062 LAQ/5063 Studies Assess Long Term Safety Tolerability Laquinimod 0.6mg RRMS Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Inclusion Criteria For 36 month extension : Subjects must complete 24 month treatment first period open label phase Women childbearing potential must practice reliable method birth control . ( Acceptable method birth control study include : double barrier method diaphragms spermicide , condom spermicide . Also intrauterine device ; hormonal contraception must accompany additional method birth control . ) Exclusion Criteria For 36 month extension : Premature discontinuation Laq/5063 OL phase prior completion 24 month treatment period pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>